Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Theravance Biopharma (TBPH) has reported Convertible Debt for 7 consecutive years, with $228.6 million the latest figure, recorded in Q2 2022.

• In Q2 2022, Convertible Debt changed 0.47% year-over-year to $228.6 million; the TTM figure through Jun 2022 stood at $228.6 million (changed 0.47% YoY), while the FY2021 annual figure was $228.0 million, changed 0.47% from the prior year.
• Convertible Debt held at $228.6 million in Q2 2022 per TBPH's latest filing, from $228.3 million in the prior quarter.
• Across five years, Convertible Debt topped out at $228.6 million in Q2 2022 and bottomed at $224.0 million in Q1 2018.
• Historically, Convertible Debt has averaged $226.3 million across 5 years, with a median of $226.3 million in 2020.
• Annual changes were most pronounced in 2018 — Convertible Debt grew 0.48% — and 2022, when it climbed 0.47%.
• Theravance Biopharma's Convertible Debt stood at $224.8 million in 2018, then grew by 0.48% to $225.9 million in 2019, then gained by 0.48% to $227.0 million in 2020, then rose by 0.47% to $228.0 million in 2021, then rose by 0.24% to $228.6 million in 2022.
• Business Quant data shows TBPH's Convertible Debt at $228.6 million in Q2 2022, $228.3 million in Q1 2022, and $228.0 million in Q4 2021.